South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
Document ID: PC-SG-101603
14/06/2022
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-SG-101603
Production date: June 2022
Production date: June 2022
- Efficacy
- GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
- GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
- GIOTRIF® provides ≥3 years long-term response even with dose modification
- Video: Uncommon EGFR pooled analysis in 693 patients
- GIOTRIF® real world experience in Asia
- GIOTRIF® in common EGFR mutations
- SEREAL||GIOTRIF® in LUX-Lung 7
- SEREAL||GIOTRIF® efficacy in the real-world
- SEREAL||GIOTRIF® RWE in Taiwan
- SEREAL||GIOTRIF® RWE in patients with brain metastases
- SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
- SEREAL||Impact of GIOTRIF® in delaying CNS progression
- GIOTRIF® in SqCC
- GIOTRIF® RWE in South Korea
- GIOTRIF® RWE in uncommon EGFR mutations
- GIOTRIF® in elderly
- Real-world evidence: GIOTRIF® in Taiwan
- SEREAL||Real-world evidence: GIOTRIF® in Japan
- SEREAL||GIOTRIF® safety and effectiveness in the real world
- South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
- RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
- RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
- Sequencing
- Publication: GioTag
- Publication: GioTag Final Analysis
- Video: GioTag Final Analysis
- SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate)
- SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS)
- SEREAL||GioTag sequence may delay time to chemotherapy
- SEREAL||GIOTRIF® sequential RWE in Japan
- GIOTRIF® followed by 3rd generation TKI in RESET study
- SEREAL||GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
- Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
- Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC
- SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
- RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies
- RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - TOAST Publication
- Safety
- Dosing and Administration
- Prescribing Information
- Expert Conversations